Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Overview of attention for article published in Journal of Clinical Oncology, December 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 7 news outlets
twitter: 37 X users

patent: 1 patent
guideline: 1 clinical guideline source

Readers on

mendeley: 103 Mendeley

So far, Altmetric has seen 9 news stories from 7 outlets.

Agenus: Novel Drugs That Just Are Not Novel

Seeking Alpha, 24 Jul 2024

Follow Summary Agenus is a small biotech company focused on developing cancer treatments, with a history of poor stock…

Dmitriy Zamarin, MD, PhD, on Novel Therapies for Cervical Cancer

MedPage Today, 23 Mar 2022

This Reading Room is a collaboration between MedPage Today® and: Novel therapies have improved outcomes in women with cervical…

David O'Malley, MD, on Dual Immunotherapy for Advanced Cervical Cancer

MedPage Today, 09 Mar 2022

This Reading Room is a collaboration between MedPage Today® and: A novel combination of the anti-programmed death-1 (PD-1…

Dual checkpoint blockade shows promising activity in advanced cervical cancer

Healio.com, 02 Feb 2022

February 02, 2022 2 min read Source/Disclosures Published by: Disclosures: Agenus Inc.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 5 additional news stories.